 BEVERLY HILLS, Calif., Sept. 8, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager, TriKE protein biologic technology platform, announced today that Anthony Cataldo, Chairman CEO, Dr. Greg Berk, President of RD and Chief Medical Officer, and Dr. Jeff Miller, Consulting Chief Scientific Officer will be presenting and hosting one-on-one meetings at the upcoming H.C. 